Pharming Group N.V (PHGUF PINK) stock market data APIs
$0.8939
0(0%)
as of March 20, 2025
Pharming Group N.V Financial Data Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Prev. Close
0.8939
Open
0.8939
High
0.8939
Low
0.8939
52 wk Range
0.745-1.2
Market Cap
611 M
Shares Outstanding
678 M
Revenue
297 M
Beta
0.639
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharming Group N.V data using free add-ons & libraries
Get Pharming Group N.V Fundamental Data
Pharming Group N.V Fundamental data includes:
- Net Revenue: 297 M
- EBITDA: 7 449 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group N.V News
New
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Pharming Group N.V. Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year e...
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Pharming Group N.V. Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for2Q 2024 Leiden, The Netherlands, December 13, 2023...
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
Pharming Group N.V. The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leid...
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
Pharming Group N.V. Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
